Fig. 3.
Anesthetic EC5 enhancement in wild-type versus α1-M1- and β3-M1-substituted tryptophan γ-aminobutyric acid (GABA) type A receptor mutants. The bar graph depicts GABA EC5 enhancement ratios (mean ± SEM) for five receptor types (x-axis labels) and four equipotent anesthetic solutions: 3.2 μM etomidate (ETO; red), 8 μM mTFD-MPAB (R-5-allyl-1-methyl-5-[m-trifluoromethyl-diazirinylphenyl] barbituric acid; green), 5 μM propofol (PRO; white), and 2.5 μM alphaxalone (ALFAX; purple). The number of oocytes studied for each interaction is indicated by the numbers in each bar. Each drug’s effect in mutants was compared to the same drug effect in wild-type (by two-way ANOVA). Differs from wild-type at **P < 0.01 and ***P < 0.001.